Key facts
- HAPPE Spine’s last known valuation is $13.3M (Feb 2023).
- It has raised $13.5M across 4 recorded rounds; the latest was Early Stage VC ($5.3M) in Aug 2021.
- Notable investors include MedTech Innovator, Michigan Rise, Cultivate(MD), Biosciences Research and Commercialization Center, Celling Biosciences — 7 tracked in total.
- HAPPE Spine has filed 6 Form Ds with the SEC since 2019, most recently Aug 2025 ($2.1M sold to 31 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for HAPPE Spine
Funding rounds
4 roundsAbout HAPPE Spine
Developer of spinal fusion implant devices designed to facilitate bone ingrowth and provide biomechanical support in spinal surgeries. The company offers devices with porous structures for bone integration, visibility during imaging, multiple sizes to suit patient anatomy, markers for placement accuracy, and structural components to enhance stability, providing surgeons the tools to perform effective spinal fusions that promote successful patient outcomes.
- Sector
- Healthcare
- HQ
- Grand Rapids, MI, United States
- Founded
- 2018
- Employees
- 8
- Website
- happeortho.com/
- Ownership
- Privately Held (backing)
HAPPE Spine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HAPPE Spine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HAPPE Spine in its N-PORT filings yet. We sweep new filings monthly.